Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A prospective study on the use of the TransLoc 3D SI Joint Fusion System for patients with sacroiliac joint disruptions or degenerative sacroiliitis.
Multicenter, prospective, post-market surveillance study on the TransLoc 3D Sacroiliac Joint Fusion System including two treatment arms: 1) Lateral-Oblique TransLoc 3D Screw(s), 2) Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid). Data from this post-market study will be used to support knowledge of clinical efficacy and improvement with the use of TransLoc 3D Sacroiliac Joint Fusion System.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lateral-Oblique TransLoc 3D Screw(s) | Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint. |
| |
| Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid) | Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TransLoc 3D | Device | TransLoc 3D SI Joint Fusion System |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical improvement at 12 months defined by a composite score of functional status, pain, and safety events. | Functional improvement and pain score have long been the standard for SI joint improvement measures. Multiple functional improvement scales will be assessed throughout the study. | 12 months |
| Absence of Serious Adverse Events (SAEs) | Demonstrate safety as defined by Serious Adverse Events (SAEs). | From the time informed consent is signed through 12 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Absence of study-related adverse events | Evaluate any study-related adverse events for the duration of the study. | 6 months, 12 months |
Not provided
Inclusion Criteria:
Subjects meeting all of the following inclusion criteria by the end of the screening phase should be considered for admission to the study:
Exclusion Criteria:
Patient will not be entered into the study if they meet one of the following criteria:
Not provided
Not provided
Consecutive enrollment of all patients within inclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Samuel Brown, DO | NY Spine and Pain Specialists | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NY Spine and Pain Specialists | Port Jefferson Station | New York | 11776 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D058566 | Sacroiliitis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided